Indegene's IPO was oversubscribed by 69.71 times on closing day, with strong demand from QIBs and non-institutional investors. Learn more about the offer details and company.
Illustration: Dominic Xavier/Rediff.com
New Delhi, May 8 (PTI) The Initial Public Offer (IPO) of healthcare tech firm Indegene got subscribed 69.71 times on the closing day of bidding on Wednesday.
The Rs 1,841.75 crore IPO received bids for 2,01,22,03,281 shares against 2,88,66,677 shares on offer, as per NSE data.
The portion for Qualified Institutional Buyers (QIBs) got subscribed a whopping 197.55 times while the part for non-institutional investors received 54.75 times subscription. The quota for Retail Individual Investors (RIIs) garnered 7.68 times subscription.
The IPO had a fresh issue of up to Rs 760 crore and an offer for sale of up to 2,39,32,732 equity shares.
The price range for the offer remained Rs 430-452 a share.
On Friday, Indegene Ltd said it raised Rs 549 crore from anchor investors.
Funds raised through the fresh issue would be used to pay debt, fund capital expenditure requirements, payment of deferred consideration for one of its past acquisitions, fund inorganic growth and general corporate purposes.
Founded in 1998, Indegene offers solutions that help enable biopharmaceutical, emerging biotech and medical devices companies to develop products, launch them in the market, and drive sales throughout their life cycle.
Kotak Mahindra Capital Company, Citigroup Global Markets India, J P Morgan India and Nomura Financial Advisory and Securities (India) are the managers to the offer.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback